[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"egfr-mutated-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:egfr-mutated-nsclc":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100578876",false,"NCT06816992","ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC","Phase 1b Study of ORIC-114 in Combination With Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC","Inclusion Criteria:\n\n* Histologically or cytologically confirmed metastatic NSCLC with a documented EGFR exon 20 insertion mutation as determined locally by any nucleic acid-based diagnostic testing method; all tests should be performed in a CLIA certified or equivalently accredited laboratory\n* Prior Therapies:\n\n  1. Dose Escalation: Patients may have previously received and progressed on or after platinum-based chemotherapy or may be treatment naïve\n  2. Dose Expansion: Patients must not have received any prior therapy; at time of enrollment, patients must decline, or be ineligible for all available standard of care therapies with proven benefit\n* Agreement and ability to undergo a pretreatment biopsy, provided the procedure is clinically feasible and not deemed unsafe by the investigator\n* Measurable disease according to RECIST 1.1\n* Patients with asymptomatic CNS metastases are eligible\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Known small cell lung cancer transformation\n* Leptomeningeal disease\n* Spinal cord compression not definitively treated with surgery or radiation\n* Prior immunotherapy\n* Past medical history of interstitial lung disease (ILD), drug induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD\n* Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably impact absorption of ORIC-114","ALL","18 Years",{"count":18,"type":19},76,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.",[25,26,27,28],"Solid Tumors","EGFR Exon 20 Insertion Mutations","NSCLC","EGFR-mutated NSCLC",[27,30,31,32,33,34],"EGFR mutations","EGFR exon20","EGFR exon 20 insertion mutations","ORIC-114","Amivantamab","RECRUITING","2026-04-21",{"date":38,"type":39},"2026-04-24","ACTUAL",{"date":41,"type":39},"2025-02-27",{"date":43,"type":19},"2027-12",{"name":45,"class":46},"ORIC Pharmaceuticals","INDUSTRY",4,{"id":49,"slug":4,"hasResults":10,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100620871","NCT07363252","Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients","Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients - REMAIN Study","REMAIN","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of radically resected IB-IIIA NSCLC with EGFR activating mutation\n* Treatment with adjuvant osimertinib (starting from September 2022, date of approval) according to clinical practice\n* Recurrence of disease during or after adjuvant therapy with osimertinib received according to clinical practice\n* Availability of tissue and\u002For liquid biopsy sample collected at the time of recurrence\n* Signed informed consent.\n\n  * Exclusion Criteria:\n* Unavailability of tissue and\u002For liquid biopsy sample collected at the time of recurrence\n* Concomitant synchronous malignancies aside from NSCLC or any concurrent and\u002For active malignancy that has required treatment within 2 years\n* Involvement in the planning and\u002For conduct of the study (applies to both investigator staff and\u002For staff at the study site).",{"count":56,"type":19},100,"OBSERVATIONAL","Retrospective-prospective observational multicentric study including radically resected EGFR-mutated NSCLC patients relapsed during or after adjuvant osimertinib, received according to clinical practice",[28],[28,61,62],"adjuvant osimertinib","Recurrence","2026-04-17",{"date":65,"type":39},"2026-04-22",{"date":67,"type":39},"2026-04-14",{"date":69,"type":19},"2028-12",{"name":71,"class":72},"Gruppo Oncologico Italiano di Ricerca Clinica","OTHER",25,""]